Compare Medpace Holdings Inc (MEDP) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Nokia Corp — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Nokia Corp trades at $10.47 (market cap $56.70B). The key difference: Nokia Corp is far larger — about 3.8× Medpace Holdings Inc's market cap, and Nokia Corp pays a 1.63% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | NOK | |
|---|---|---|
Market Cap | $15.08B | $56.70B |
Sector | Technology | Technology |
52-Week High | $620.59 | $16.83 |
52-Week Low | $308.88 | $4.05 |
Enterprise Value | $14.55B | $53.51B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Nokia (NOK) trades at $10.115, down 0.05% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates, but has beaten expectations in prior quarters. Revenue for 2025 was $19.89B with a net income margin of 3.98%, while the P/E ratio stands at 63.48, indicating a premium valuation. Recent news highlights Nokia's strategic pivot to AI-powered networking, including partnerships with Nvidia and telecom providers.
The outlook for NOK is cautiously optimistic, driven by AI and 5G demand, but high valuation and recent earnings miss pose risks. Analyst consensus is a Buy with a $18.00 price target, suggesting significant upside. Key risks include execution on AI initiatives, competitive pressures, and supply chain constraints. The stock's performance hinges on delivering sustained growth from its AI infrastructure investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
